



(51) International Patent Classification:

C12N 15/85 (2006.01) C07K 16/46 (2006.01)
A01K 67/027 (2006.01)

(21) International Application Number:

PCT/GB2012/052296

(22) International Filing Date:

18 September 2012 (18.09.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1116122.1	19 September 2011 (19.09.2011)	GB
1116120.5	19 September 2011 (19.09.2011)	GB
1203257.9	24 February 2012 (24.02.2012)	GB
1204592.8	15 March 2012 (15.03.2012)	GB
1205702.2	29 March 2012 (29.03.2012)	GB
1208749.0	18 May 2012 (18.05.2012)	GB
1211692.7	2 July 2012 (02.07.2012)	GB

(71) Applicant (for all designated States except US): **KYMA B LIMITED** [GB/GB]; Meditrina (B260), Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB).

(72) Inventors; and

(71) Applicants (for US only): **BRADLEY, Allan** [GB/GB]; c/o Kymab Limited, Meditrina (B260), Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). **FRIEDRICH, Glenn** [GB/GB]; c/o Kymab Limited, Meditrina (B260), Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). **LEE, E-Chiang** [US/GB]; c/o Kymab Limited, Meditrina (B260), Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). **STRIVENS, Mark** [—/GB]; c/o Kymab Limited, Meditrina (B260), Babraham Research Campus, Cambridge c CB22 3AT (GB). **ENGLAND, Nicholas** [GB/GB]; c/o Kymab Limited, Meditrina (B260), Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB).

(74) Agents: **STEPHEN, Robert** et al.; Olswang LLP, 90 High Holborn, London Greater London WC1V 6XX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,

[Continued on next page]

(54) Title: ANTIBODIES, VARIABLE DOMAINS & CHAINS TAILORED FOR HUMAN USE

Recombineered BAC Vectors to add Polymorphic V-regions to the Mouse Genome

1. Cassette Exchange – Replace existing V-regions




Figure 1

(57) Abstract: The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells, such as transgenic mice or rats or transgenic mouse or rat cells. Furthermore, the invention relates to methods of using the vertebrates to isolate antibodies or nucleotide sequences encoding antibodies. Antibodies, heavy chains, polypeptides, nucleotide sequences, pharmaceutical compositions and uses are also provided by the invention.



RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*